Gabrielle Lakusta

Gabrielle grew up in the Lower Mainland of B.C. and has lived in Vancouver since 2011. She holds an Associate of Arts Degree from Langara College, and a Bachelors of Arts Major in Journalism from Kwantlen Polytechnic University. Now, she writes for INN focusing on Life Science Investing. Aside from work, Gabrielle enjoys travelling, and enjoying the outdoors—especially when hiking and cycling.

glakusta@resourceinvestingnews.com

Articles

This is the Year for NurOwn’s Stem Cell Phase 3 ALS Development

Brainstorm Cell Therapeutics' management team discusses an ongoing ALS Phase 3 clinical trial, the company's technology and more.

January 20th, 2019

Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression

Kura Oncology (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings identifying...

January 18th, 2019

Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz

Precision Therapeutics (NASDAQ:AIPT) announced that its chief executive officer and director, Carl Schwartz, has made an additional investment of $1,000,000...

January 18th, 2019

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study

Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial...

January 18th, 2019

AVROBIO Announces Acceptance of Investigational New Drug (IND) Application

AVROBIO (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared...

January 18th, 2019

Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government

Bavarian Nordic (OMX:BAVA,OTC:BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under...

January 18th, 2019

Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has received a Complete Response Letter...

January 18th, 2019